Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

AZ’s bet on Daiichi’s rival to Kadcyla pays off

Pivotal phase 2 data backs investment

Sanofi reception

Sanofi’s Dupixent gains asthma approval in Europe

Drug on track to meet blockbuster forecasts

- PMLiVE

Bicycles Therapeutics enters dementia discovery with venture capital fund

Ambitious UK biotech expands research scope

- PMLiVE

World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer

Ovarian cancer is the second most lethal gynaecological cancer worldwide. To raise awareness of this often fatal disease, our article looks at its symptoms, current treatments and future therapies.

Porterhouse Medical Group

Stream on

The Netflix model and why it (kind of) works in healthcare

- PMLiVE

Novartis builds case for SMA gene therapy as FDA verdict looms

One shot therapy provided rapid improvement in motor function

Deep Value

Value-based healthcare is difficult because it’s deep

- PMLiVE

Lundbeck snaps up Abide Therapeutics for $400m

Also acquires its lead drug for Tourette’s syndrome

- PMLiVE

Speedy approval for Pfizer’s Onpattro rival

Approved in two different formulations

Biomarin

EU nod for BioMarin’s second PKU therapy Palynziq

Palyniq is significant, but gene therapy pipeline most anticipated

- PMLiVE

Cultivating a learner-led culture: agile learning and the growth mindset

Organisations that follow traditional models of learning and development will falter

The problem with the ‘recovery’ conversation in mental health

Account Executive Loredana Gogoescu discusses the impact our language can have on people experiencing mental illness, and asks if terms such as 'recovery' are appropriate.

Blue Latitude Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links